

# Gilles W De Keulenaer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4425217/publications.pdf>

Version: 2024-02-01

132  
papers

13,064  
citations

53794

45  
h-index

22832

112  
g-index

132  
all docs

132  
docs citations

132  
times ranked

14959  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering. <i>Current Problems in Cardiology</i> , 2023, 48, 101212.	2.4	1
2	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	2.6	5
3	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. <i>Biomolecules</i> , 2022, 12, 484.	4.0	11
4	Urocortins as biomarkers in cardiovascular disease. <i>Clinical Science</i> , 2022, 136, 1-14.	4.3	1
5	Scientists on the Spot: Inflammation in atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, e7-e8.	3.8	2
6	A special case of hypertrophic cardiomyopathy with a differential diagnosis of isolated cardiac amyloidosis or junctophilin type 2 associated cardiomyopathy. <i>Acta Clinica Belgica</i> , 2021, 76, 136-143.	1.2	6
7	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. <i>Cardiovascular Research</i> , 2021, 117, e10-e12.	3.8	0
8	Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets. <i>Journal of the American Heart Association</i> , 2021, 10, e019169.	3.7	28
9	Avalanching nanoparticles bring new light to cardiovascular imaging. <i>Cardiovascular Research</i> , 2021, 117, e60-e63.	3.8	1
10	Scientist on the Spot: Exploring the cause and cure for pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2021, 117, e82-e83.	3.8	0
11	Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H2416-H2428.	3.2	8
12	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2021, 14, e006898.	3.9	12
13	The role of endothelial miRNAs in myocardial biology and disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 138, 75-87.	1.9	20
14	Mobile cardiology during the COVID-19 outbreak. <i>Cardiovascular Research</i> , 2020, 116, e149-e151.	3.8	7
15	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. <i>Frontiers in Pediatrics</i> , 2020, 8, 342.	1.9	35
16	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2020, 889, 173658.	3.5	7
17	Sex differences in circulating proteins in heart failure with preserved ejection fraction. <i>Biology of Sex Differences</i> , 2020, 11, 47.	4.1	12
18	The role of ErbB4 in cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 335-352.	4.4	66

#	ARTICLE	IF	CITATIONS
19	The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H443-H455.	3.2	23
20	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). <i>Biomarkers</i> , 2020, 25, 201-211.	1.9	26
21	Ex vivo aortic stiffness in mice with different eNOS activity. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H1233-H1244.	3.2	18
22	Long-term impact of a six-month telemedical care programme on mortality, heart failure readmissions and healthcare costs in patients with chronic heart failure. <i>Journal of Telemedicine and Telecare</i> , 2019, 25, 286-293.	2.7	37
23	Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006288.	3.9	44
24	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 599-613.	2.6	7
25	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	7.1	182
26	Cardiac endothelial cell transcriptome in neonatal, adult, and remodeling hearts. <i>Physiological Genomics</i> , 2019, 51, 186-196.	2.3	9
27	Vascular smooth muscle cell contraction and relaxation in the isolated aorta: a critical regulator of large artery compliance. <i>Physiological Reports</i> , 2019, 7, e13934.	1.7	41
28	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
29	Epigenetic regulation of intercellular communication in the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H1417-H1425.	3.2	9
30	Neuregulin-1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 255-265.	1.9	11
31	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.2	123
32	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 932-948.	1.6	74
33	Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 204-215.	1.9	39
34	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018, 114, 880-893.	3.8	52
35	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2018, 114, 1165-1177.	3.8	19
36	Neuregulin-1 attenuates stress-induced vascular senescence. <i>Cardiovascular Research</i> , 2018, 114, 1041-1051.	3.8	32

#	ARTICLE	IF	CITATIONS
37	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
38	Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1. <i>Circulation Research</i> , 2018, 123, 342-355.	4.5	64
39	Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO. <i>Frontiers in Physiology</i> , 2018, 9, 382.	2.8	121
40	Short-Term Angiotensin II Treatment Affects Large Artery Biomechanics and Function in the Absence of Small Artery Alterations in Mice. <i>Frontiers in Physiology</i> , 2018, 9, 582.	2.8	16
41	The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function. <i>European Journal of Heart Failure</i> , 2017, 19, 603-614.	7.1	27
42	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. <i>Experimental Physiology</i> , 2017, 102, 411-421.	2.0	5
43	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.1	115
44	Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H934-H945.	3.2	63
45	Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E495-E504.	3.5	32
46	ErbB2 signaling at the crossing between heart failure and cancer. <i>Basic Research in Cardiology</i> , 2016, 111, 60.	5.9	68
47	Pulmonary arterial hypertension: Basic knowledge for clinicians. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 550-561.	1.6	34
48	A novel setup for the <i>ex vivo</i> analysis of mechanical properties of mouse aortic segments stretched at physiological pressure and frequency. <i>Journal of Physiology</i> , 2016, 594, 6105-6115.	2.9	36
49	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 312-324.	4.1	390
50	Effect of angiotensin II-induced arterial hypertension on the voltage-dependent contractions of mouse arteries. <i>Pflügers Archiv European Journal of Physiology</i> , 2016, 468, 257-267.	2.8	17
51	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2016, 109, 44-54.	3.8	33
52	Cardiotoxicity of Cancer Chemotherapy—Recent Developments. , 2016, , 36-83.		1
53	Cardiac endothelium—myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. <i>European Heart Journal</i> , 2015, 36, 2050-2060.	2.2	126
54	Letter by Brutsaert and De Keulenaer Regarding Article, “Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction”. <i>Circulation: Heart Failure</i> , 2015, 8, 839-839.	3.9	3

#	ARTICLE	IF	CITATIONS
55	Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. <i>European Heart Journal</i> , 2015, 36, 1049-1058.	2.2	139
56	Urocortin 2 in cardiovascular health and disease. <i>Drug Discovery Today</i> , 2015, 20, 906-914.	6.4	25
57	Chronic intermittent mental stress promotes atherosclerotic plaque vulnerability, myocardial infarction and sudden death in mice. <i>Atherosclerosis</i> , 2015, 242, 288-294.	0.8	42
58	P505Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2014, 103, S92.4-S92.	3.8	0
59	P755Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2014, 103, S138.3-S138.	3.8	0
60	Applanation Tonometry in Mice. <i>Hypertension</i> , 2014, 64, 195-200.	2.7	33
61	Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. <i>Cardiovascular Research</i> , 2014, 104, 423-431.	3.8	70
62	Therapeutic potential of neuregulin-1 in cardiovascular disease. <i>Drug Discovery Today</i> , 2013, 18, 836-842.	6.4	49
63	Pathophysiology of diastolic dysfunction in chronic heart failure. <i>Future Cardiology</i> , 2013, 9, 711-720.	1.2	7
64	Impact of Radiofrequency Characteristics on Acute Pulmonary Vein Reconnection and Clinical Outcome After PVAC Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 290-296.	1.7	19
65	Cardiotoxicidade associada À terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 395-409.	0.5	62
66	Phenotypical characterization of Î±-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1088-1093.	1.4	31
67	Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 395-409.	0.2	30
68	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	27.0	462
69	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	7.4	297
70	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , 2013, 34, 3117-3127.	2.2	53
71	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (REDâ€œHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	7.1	24
72	Pathophysiology of Heart Failure: Back to Basics. , 2013, , 3-23.		1

#	ARTICLE	IF	CITATIONS
73	Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics. International Journal of Molecular Sciences, 2012, 13, 12268-12286.	4.1	40
74	Prevalence, Characteristics, and Predictors of Pulmonary Vein Narrowing After Isolation Using the Pulmonary Vein Ablation Catheter. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 52-60.	4.8	34
75	Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction. Current Opinion in Cardiology, 2012, 27, 273-280.	1.8	36
76	Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMACHF 1 (Telemonitoring) Trial. JAMA, 2012, 307, 1075-1083.	0.1	0
77	Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure, 2012, 14, 219-225.	7.1	158
78	DPP4 inhibition may ameliorate bone turnover in diabetic mice. Bone, 2012, 50, S171.	2.9	0
79	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biological Chemistry, 2011, 392, 189-98.	2.5	66
80	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
81	Effects of Nebivolol on Vascular Endothelial and Myocardial Function in Diabetes Mellitus. Journal of Cardiovascular Pharmacology, 2011, 58, 56-64.	1.9	6
82	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	7.1	350
83	Systolic and Diastolic Heart Failure Are Overlapping Phenotypes Within the Heart Failure Spectrum. Circulation, 2011, 123, 1996-2005.	1.6	114
84	HEART FAILURE WITH A PRESERVED EJECTION FRACTION: FROM PATHOPHYSIOLOGY TO BIOMARKERS AND BEYOND!. The European Journal of Cardiovascular Medicine, 2011, 1, .	1.0	0
85	Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H931-H942.	3.2	66
86	Paving new paths for neuregulin-1-assisted cardiac regenerative medicine. Focus on improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: differential expression of microRNAs. American Journal of Physiology - Cell Physiology, 2011, 301, C16-C17.	4.6	5
87	Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology, 2010, 99, 75-82.	3.3	14
88	Role of autophagy in heart failure associated with aging. Heart Failure Reviews, 2010, 15, 423-430.	3.9	103
89	The Vulnerability of the Heart As a Pluricellular Paracrine Organ. Circulation Research, 2010, 106, 35-46.	4.5	177
90	Pulmonary vein stenosis after pulmonary vein ablation catheter-guided pulmonary vein isolation. Heart Rhythm, 2010, 7, 1306-1308.	0.7	14

#	ARTICLE	IF	CITATIONS
91	The Heart Failure Spectrum. <i>Circulation</i> , 2009, 119, 3044-3046.	1.6	40
92	Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 33-38.	1.9	29
93	Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. <i>Pflugers Archiv European Journal of Physiology</i> , 2008, 455, 811-818.	2.8	32
94	Normal Physiology and Pathophysiology of Left Ventricular Diastole. , 2008, , 52-62.		0
95	Molecular Mechanisms of Diastolic Dysfunction. , 2008, , 3-19.		1
96	Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy. <i>European Journal of Heart Failure</i> , 2007, 9, 352-356.	7.1	13
97	Systolic and diastolic heart failure: Different phenotypes of the same disease?. <i>European Journal of Heart Failure</i> , 2007, 9, 136-143.	7.1	66
98	Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease. <i>Circulation</i> , 2007, 116, 954-960.	1.6	230
99	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 2539-2550.	2.2	2,302
100	Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure. <i>Experimental Hematology</i> , 2007, 35, 1884-1890.	0.4	35
101	Diastolic Heart Failure: A Separate Disease or Selection Bias?. <i>Progress in Cardiovascular Diseases</i> , 2007, 49, 275-283.	3.1	36
102	Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H1370-H1377.	3.2	183
103	Diastolic heart failure: a myth. <i>Current Opinion in Cardiology</i> , 2006, 21, 240-248.	1.8	57
104	Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk. <i>Journal of Biological Chemistry</i> , 2006, 281, 19469-19477.	3.4	154
105	Cardiomyopathy and thyrotoxicosis. <i>Acta Cardiologica</i> , 2006, 61, 115-117.	0.9	11
106	Inhibition of heme oxygenase?1 impairs cardiac muscle sensitivity to beta?adrenergic stimulation. <i>Basic Research in Cardiology</i> , 2005, 100, 224-230.	5.9	4
107	Letter Regarding Article by Okoshi et al, "Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of I <sup>2</sup> -Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion" <i>Circulation</i> , 2005, 111, e175; author reply e175.	1.6	7
108	Urgent need to reorganize heart failure management. <i>Acta Cardiologica</i> , 2005, 60, 179-184.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle. <i>Circulation</i> , 2004, 109, 324-326.	1.6	99
110	Molecular diversity of cardiac endothelial cells in vitro and in vivo. <i>Physiological Genomics</i> , 2004, 19, 198-206.	2.3	33
111	Endocardial endothelium modulates subendocardial pHi of rabbit papillary muscles: role of transendothelial HCO <sub>3</sub> <sup>-</sup> transport. <i>Cardiovascular Research</i> , 2004, 63, 700-708.	3.8	5
112	Biomechanically Induced Gene iex-1 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation. <i>Circulation Research</i> , 2003, 93, 1210-1217.	4.5	35
113	145 Gene transfer of the mechanically induced gene IEX-I inhibits cardiac hypertrophy in vivo. <i>European Heart Journal</i> , 2003, 24, 12.	2.2	0
114	Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. <i>Circulation</i> , 2002, 106, 2961-2966.	1.6	551
115	Identification of IEX-1 as a Biomechanically Controlled Nuclear Factor- $\kappa$ B Target Gene That Inhibits Cardiomyocyte Hypertrophy. <i>Circulation Research</i> , 2002, 90, 690-696.	4.5	58
116	Vitamin D3-up-regulated Protein-1 Is a Stress-responsive Gene That Regulates Cardiomyocyte Viability through Interaction with Thioredoxin. <i>Journal of Biological Chemistry</i> , 2002, 277, 26496-26500.	3.4	159
117	Vitamin D 3 $\alpha$ -Upregulated Protein-1 (VDUP-1) Regulates Redox-Dependent Vascular Smooth Muscle Cell Proliferation Through Interaction With Thioredoxin. <i>Circulation Research</i> , 2002, 91, 689-695.	4.5	136
118	Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H533-H539.	3.2	32
119	Activation of Cardiac Endothelium as a Compensatory Component in Endotoxin-Induced Cardiomyopathy. <i>Circulation</i> , 2001, 104, 3137-3144.	1.6	45
120	Convergence of Redox-Sensitive and Mitogen-Activated Protein Kinase Signaling Pathways in Tumor Necrosis Factor- $\alpha$ -Mediated Monocyte Chemoattractant Protein-1 Induction in Vascular Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 385-391.	2.4	85
121	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. <i>Journal of Cardiac Surgery</i> , 1999, 14, 64-74.	0.7	17
122	Oscillatory and Steady Laminar Shear Stress Differentially Affect Human Endothelial Redox State. <i>Circulation Research</i> , 1998, 82, 1094-1101.	4.5	567
123	Cardiac endothelium and myocardial function. <i>Cardiovascular Research</i> , 1998, 38, 281-290.	3.8	107
124	Physiopharmacological evaluation of myocardial performance how to study modulation by cardiac endothelium and related humoral factors?. <i>Cardiovascular Research</i> , 1998, 39, 136-147.	3.8	15
125	Reappraisal of the Multicellular Preparation for the In Vitro Physiopharmacological Evaluation of Myocardial Performance. <i>Advances in Experimental Medicine and Biology</i> , 1998, 453, 441-451.	1.6	12
126	Angiotensin II-Induced Hypertension Increases Heme Oxygenase-1 Expression in Rat Aorta. <i>Circulation</i> , 1997, 96, 1923-1929.	1.6	98

#	ARTICLE	IF	CITATIONS
127	Endocardial-Myocardial Interaction. , 1997, , 163-178.		0
128	Endocardial endothelial dysfunction and heart failure. Journal of Cardiac Failure, 1996, 2, S195-S202.	1.7	17
129	The cardiac endothelium: Functional morphology, development, and physiology. Progress in Cardiovascular Diseases, 1996, 39, 239-262.	3.1	65
130	Decreased myocardial contractility after damage to endocardial endothelium is not merely caused by loss of endothelin production. Cardiovascular Research, 1995, 30, 646-647.	3.8	4
131	Endothelin-Mediated Positive Inotropic Effect Induced by Reactive Oxygen Species in Isolated Cardiac Muscle. Circulation Research, 1995, 76, 878-884.	4.5	35
132	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. Echocardiography, 1985, 2, 64-72.	0.9	0